Haya Therapeutics is a Switzerland-based company that is researching RNA-therapeutics, specifically on long noncoding RNA.It is in the pre-clinical stages of its research and testing. It has the stated goal of being the first company to translate its research on long noncoding RNA to treat to heart failure.
The company is researching the RNA molecule that causes the scarring which leads to heart failure. It utilizes the knowledge of Wisper (Wisp2 super-enhancer-associated RNA) to treat the underlying causes of heart failure. It is developing a method to inject a modified DNA molecule that would affect the Wisper. Haya Therapeutics is testing its research on animals with the stated intention of eventually testing and treating humans. As of 2019, the test results have been successful in preventing the development of heart failure in animal testing.
The company is funded by several investors, such as Venture Kick and Start Lab.It has had four funding rounds: two grants, one seed, and one debt financing round.
Daniel Blessing, PhD
CTO and Co-Founder
Samir Ounzain, PhD
CEO and Co-Founder
Thierry Pedrazzini, PhD
Chair of the Scientific Advisory Board
Haya Therapeutics, aux racines de l'insuffisance cardiaque
April 17, 2019
Documentaries, videos and podcasts
HAYA Therapeutics 2019 Venture winner
July 8, 2019